6 research outputs found
Recommended from our members
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer.
We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients
Cellular phones in clinical teledermatology
We read with interest the article by Braun et al,1 who merely demonstrated the feasibility of telemedical wound care consultation via a new generation of cellular phones. In this context, we would like to share our experience with cellular phones and patients with typical skin conditions in a routine clinical setting. A total of 95 patients (male-female ratio, 39:56; mean age, 49 years; median age, 46 years; and age range, 6-90 years) were selected consecutively in the outpatient service of the Department of Dermatology, Medical University of Graz, Graz, Austria, in July 2003. Patients who presented for the first time and who were referred for all skin conditions except melanocytic lesions were included. Only patients who agreed and signed the patient consent form were enrolled. A face-to-face diagnosis was always formulated by the same board-certified dermatologist (I.Z.). A medical student (E.W.) acquired the images (under routine conditions, with no additional . . . [from full text of this article